A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

NCT04822701 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped not due to safety reasons

Conditions

COVID-19

Interventions

DRUG: BI 767551 intravenous
DRUG: BI 767551 inhaled
DRUG: Placebo intravenous
DRUG: Placebo inhaled

Sponsor

Boehringer Ingelheim